Our Story
The tools didn't exist. So we built them.
Every systematic review we ran followed the same pattern: months of manual work, decisions buried in spreadsheets, errors that surfaced too late to trace, and evidence that aged faster than we could publish it. We knew something had to change — because we were the ones living with the consequences.
We are physicians and medical researchers working across leading academic medical centers and research institutions in the United States, with collaborators at healthcare systems internationally, including the NHS. For years, we shared the same frustrations: multi-site studies slowed by institutional bureaucracy, screening workflows where more than one in ten decisions contained errors, and completed reviews that became outdated before they could shape clinical guidelines.
We didn't set out to start a technology company. We set out to solve a problem we encountered every day. The gap between what evidence synthesis demands and what existing tools provide had been widening for years — and no one was building what we actually needed.
By early 2025, that changed. A new generation of AI infrastructure reached the level of reliability required for research-grade applications — capable enough to handle the mechanical burden of evidence synthesis, while keeping researchers in full control of every scientific judgment. That moment of convergence brought our clinical researchers together with engineers from leading medical technology companies who understood both the technical possibilities and the regulatory realities of healthcare software.
Together, we made a decision: stop adapting to tools that weren't designed for how research actually works, and start building the infrastructure that should have existed all along. Mapped Technologies is the result — a company founded by the people who use the tools, for the people who use the tools.
The Problem
Medical evidence is the foundation of patient care. The process for producing it is failing.
1,139
hours per systematic review
Cashion, 2025
10.76%
human screening error rate
Wang et al., PLOS ONE
28%
of protocols never completed
Cochrane Bibliographic Study
64.3%
of reviews never updated
TMC, 2024
Consider the scale of the problem. A single systematic review consumes an average of 1,139 hours — nearly eight months of full-time effort distributed across a research team. Human reviewers make errors in more than one out of every ten screening decisions. Nearly a third of registered review protocols are abandoned before completion. And of the reviews that do reach publication, almost two-thirds are never updated.
The evidence that clinical guidelines depend on is being produced by a process that is slow, error-prone, and largely manual. When Cochrane attempted living systematic reviews during COVID-19 — the moment when continuously updated evidence mattered most — half of their living reviews went unmodified by mid-2023. Only one in twenty-five successfully communicated its living status to readers.
Meanwhile, the regulatory environment is accelerating. The FDA launched its RWE-ACCELERATE initiative and shifted to accepting a single pivotal trial for drug approval. The EMA's DARWIN EU network now spans 40 data partners covering 160 million patients. Regulators are building the infrastructure for continuous evidence. The question is whether the research community has the tools to meet them there.
Our Vision
From tools that assist to infrastructure that transforms
The evidence synthesis landscape today includes 388 identified AI tools. Only 2% of them attempt end-to-end automation. The rest address individual steps — screening assistants, extraction helpers, statistical calculators. Useful in isolation. Insufficient for the shift that regulators, institutions, and patients are demanding.
We are building something different: complete, production-grade research platforms that cover the full evidence lifecycle. Not tools that assist one step of a broken workflow, but infrastructure that reimagines the workflow itself — where AI handles the mechanical burden and researchers retain full authority over every scientific decision.
Our first product, mapped, covers the complete systematic review workflow from research question to published manuscript. Our next — a living evidence platform for drug interventions and diagnostic accuracy — is designed for the regulatory world that is already taking shape: one where evidence is expected to stay current, auditable, and ready for submission at any point, not published once and left to gather dust.
We believe the next decade of medical research will be defined by the quality of its infrastructure. We intend to build it.
Corporate Information
Mapped Technologies LLC
30 N Gould St, STE R
Sheridan, WY 82801, USA
Wyoming limited liability company